BPC157 as Potential Agent Rescuing from Cancer Cachexia
- Authors
- Kang, Eun A.; Han, Young-Min; An, Jeong Min; Park, Yong Jin; Sikiric, Predrag; Kim, Deok Hwan; Kwon, Kwang An; Kim, Yoon Jae; Yang, Donghwa; Tchah, Hann; Hahm, Ki Baik
- Issue Date
- 2018
- Publisher
- BENTHAM SCIENCE PUBL LTD
- Keywords
- Cancer cachexia; BPC157; muscle atrophy; cytoprotection; hypercatabolism; hypoanabolism
- Citation
- CURRENT PHARMACEUTICAL DESIGN, v.24, no.18, pp.1947 - 1956
- Journal Title
- CURRENT PHARMACEUTICAL DESIGN
- Volume
- 24
- Number
- 18
- Start Page
- 1947
- End Page
- 1956
- URI
- https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/5255
- DOI
- 10.2174/1381612824666180614082950
- ISSN
- 1381-6128
- Abstract
- Cancer cachexia, one of the metabolic syndromes caused by cancer, is a devastating and miserable condition encountered in more than 50% of terminal cancer patients presenting with significant weight loss associated with skeletal muscle atrophy and fat loss. Though cachexia may account for up to 20% of cancer deaths, no significant treatment is still lacking and is of urgent unmet medical need in cancer treatment. Therefore, understanding the underlying molecular mechanisms is essential for anticipating therapeutic approaches. Since the primary events driving cachexia are mediated via either the central nervous system related-or inflammation related-anorexia, hypoanabolism, and hypercatabolism, therapy usually targets nutritional support to compensate reduced food intake along with some anti-inflammatory agents to cover specific inflammation-related metabolic derangement, and encourages exercise to supplement reduced physical activity, but all proven to be not so effective so far. Therefore, combination therapies such as a standard multi-modal package including an anorexic agent, megestrol acetate, and anti-inflammatory agent coupled with the development of potential novel therapeutics promise a new era in rescuing patients from cancer cachexia. In this review, we propose the potential application of BPC157, one of the active cytoprotective agents isolated from gastric juices for cancer cachexia. Before clinical trial, we introduced the evidence showing BPC157 rescued from cancer cachexia supported with explored mode of actions,
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 의과대학 > 의학과 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/5255)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.